|
|
Upfront Briefing
Biotech came into Monday with the tape still acting healthier than the broad market and the newsflow doing its part. Ipsen opened the weekend by buying Kartos to add navtemadlin in myelofibrosis, while Viridian got its FDA nod in thyroid eye disease and moved from science project to launch story. Less cheerful: Tavneos picked up a deeper regulatory cloud in Europe, a reminder that marketed assets can still get dragged back into the penalty box.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,354.0 |
0.0% |
7.2% |
| Nasdaq 100 |
29,118.2 |
(1.1%) |
15.5% |
| Russell 2000 |
3,010.1 |
0.1% |
20.0% |
| Healthcare (XLV) |
160.3 |
3.0% |
3.1% |
| Biotech (XBI) |
155.4 |
2.5% |
27.9% |
| Nasdaq Biotech (NBI) |
6,480.0 |
2.3% |
13.6% |
| Clinical Trials (BBC) |
51.1 |
2.9% |
35.7% |
|
- Biotech outran the broad tape on a deal-heavy week — XBI +2.5%, NBI +2.3% — led by Bio-Techne (up ~22% on the week into Merck KGaA's $11.3B buyout) and Incyte (~15%), with healthcare the best-performing S&P sector.
- The broad tape stalled — S&P 500 flat and the Nasdaq logging a fifth straight down day — as chips slid on a report that OpenAI may push its IPO into 2027; crude fell roughly 3.7% as Strait of Hormuz traffic normalized and gold firmed.
- Market data: U.S. cash close Friday, 26 June 2026.
The Big 3
|
1
|
Ipsen to acquire Kartos Therapeutics
|
- Navtemadlin, an investigational oral MDM2 inhibitor in myelofibrosis, anchors Ipsen's acquisition of Kartos Therapeutics, adding a Phase 3 hemato-oncology asset with top-line POIESIS data due in 2027.
- Why it matters: Ipsen pays $450M upfront and up to $1.3B in milestones (a significant regulatory approval payment plus sales-based steps), with close targeted for end-Q3 2026 and a potential launch as early as 2028. Navtemadlin is an add-on to ruxolitinib for suboptimal responders, not a standalone — so the thesis rides on whether the POIESIS combination readout converts Kartos's early add-on signal into durable, disease-modifying benefit. At roughly $1.75B all-in for one late-stage asset with a 2027 data gate, this is a milestone-weighted, data-contingent bet, not a de-risked revenue add.
- Source: PR
|
|
2
|
FDA approves Viridian's veligrotug for thyroid eye disease
|
- The FDA approved Lumvoa (veligrotug-vvze), Viridian's first commercial product, for thyroid eye disease across both active and chronic disease — a first-in-class broad label.
- Why it matters: Approval flips Viridian (VRDN) from binary regulatory risk to an execution story against Amgen's Tepezza, the only TED therapy since 2020. The pivotal read was strong — 70% vs 5% proptosis response in active disease (THRIVE) and 56% vs 8% in chronic (THRIVE-2), on a five-infusion, 12-week IV course. From here the drivers are launch uptake, payer coverage and infusion logistics against an entrenched incumbent; the swing factor is whether the broad active-plus-chronic label converts into share rather than just splitting the category.
- Source: MedCity News
- More: FirstWord Pharma; Ophthalmology Times
|
| 3 | EU regulators move to revoke Tavneos authorization |
- Tavneos faces a revocation recommendation in Europe, with regulators citing data integrity concerns around the approval basis.
- Why it matters: This is a marketed-asset problem, not a preclinical setback. If the CHMP recommendation stands, investors have to haircut the durability of ex-U.S. revenue from Tavneos and also factor in higher regulatory and compliance scrutiny tied to the handling of pivotal-trial data.
-
Source:
PR
-
More:
BioCentury; EMA
|
Everything Else that broke
- Epicrispr's epigenetic editor EPI-321 delivered the first clinical evidence of muscle gain in facioscapulohumeral muscular dystrophy — three low-dose Phase 1/2 patients averaged ~0.8 lb more lean muscle at six months with no serious AEs — in a field where Sanofi/Fulcrum and Roche have failed and Sarepta and Novartis (via its $12B Avidity buy) are still racing. — Fierce Biotech
- Moderna unveiled its first in vivo CAR-T, mRNA-6007, an off-the-shelf LNP-delivered candidate that reprograms T cells to clear pathogenic B cells in B-cell-mediated autoimmune disease (a lupus-led basket), with clinic entry slated for 2027 — bringing a large mRNA balance sheet into a space so far led by ex vivo CD19 CAR-T players. — Fierce Biotech
- FDA advisory-panel chatter returned to the tape around Capricor’s Aug. 22 deramiocel PDUFA, while Replimune separately disclosed plans to resubmit RP1 after discussions with FDA. — Capricor; Replimune
- House proposals would tighten China biotech investment and in-licensing, adding friction to a key asset-sourcing channel. — BioCentury
- The EU opened formal antitrust proceedings against Sanofi over alleged conduct tied to Efluelda flu-vaccine marketing. — El País
- Health Canada approved Bavarian Nordic's VIMKUNYA chikungunya vaccine for people 12 and older. — PR
- EU Biotech Act proposals stayed in focus as Brussels and member states pushed measures intended to speed biotech innovation and strengthen manufacturing capacity. — European Commission
- Roche launched AXELIOS 1, an SBX-based next-generation sequencing platform focused on speed, scalability and cost efficiency. — PR
- CHMP backed TECVAYLI plus daratumumab for earlier use in relapsed or refractory multiple myeloma. — PR
- FDA issued seven Form 483 observations to Dr. Reddy's Hyderabad biologics plant after a mid-June inspection. — Fierce Pharma
- AB Science completed phase 1 step 3 for AB8939 plus venetoclax in relapsed or refractory AML. — PR
- 4DMedical won Australian approval for CT:VQ, a non-contrast ventilation-perfusion imaging product from routine chest CT scans. — PR
- Siren Biotechnology landed an $8M non-dilutive CIRM grant to support SRN-101 in high-grade glioma. — PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Universe Pharmaceuticals will buy Best Praise for $10.75M in stock, adding five China patents. — PR
- Neuphoria said it is in talks with Scancell on a possible combination, with no terms disclosed. — PR
- Edison Scientific and Population Health Partners teamed up to create new biotechs using AI agents. — STAT
VC / Private Financings
- Decoy Therapeutics lined up up to $21M in private-placement financing for its multi-antiviral platform; no investor syndicate was disclosed in the company announcement. — PR
IPOs / Follow-Ons
- Definium's $805M follow-on led a nearly $1.5B four-deal biotech equity burst with uniQure, MoonLake and Taysha. — BioCentury
Academic Corner - A Lancet editorial spotlights rising early-onset cancer in younger adults, framing it as a system-level prevention, screening and survivorship challenge rather than a narrow epidemiology story. — Lancet
|
One drug approved, one un-approved, and one bought before it's even read out. Peak biotech Monday. — BioBucks Team
|
|
|
